Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22695465 | 0.85 | MAP4K1 (0.44) | MAP4K1OTUD7B | |
| SCHEMBL22803132 | 0.80 | MAP4K1 (0.42) | MAP4K1OTUD7B | |
| SCHEMBL21353484 | 0.73 | NR3C2 (0.37) | MAP4K1 | |
| SCHEMBL29422873 | 0.72 | MAP4K1 (0.41) | MAP4K1 | |
| SCHEMBL22695582 | 0.72 | MAP4K1 (0.41) | MAP4K1 | |
| SCHEMBL31553232 | 0.71 | MAP4K1 (0.32) | MAP4K1 | |
| SCHEMBL21352872 | 0.70 | OTUD7B (0.44) | MAP4K1OTUD7B | |
| SCHEMBL22695464 | 0.70 | OTUD7B (0.44) | MAP4K1OTUD7B | |
| SCHEMBL21827620 | 0.69 | — | — | |
| SCHEMBL29515690 | 0.69 | PARP1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11453681-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20200392153-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2020237025-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020237025-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453681-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | MAP4K1 122/4885OTUD7B 1342/4885 |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | MAP4K1 122/4885OTUD7B 1342/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | MAP4K1 122/4885OTUD7B 1342/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | MAP4K1 50/4885OTUD7B 1132/4885 |
| US-20200392153-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | MAP4K1 122/4885OTUD7B 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.